代谢综合征严重程度Z评分用于追踪糖尿病前期治疗中的风险:DPP分析
基于DPP中2476例糖尿病前期成人,分析生活方式、二甲双胍或安慰剂治疗2-3年及随访至2014年的数据,发现1年时MetS-Z及组分变化与T2DM和CVD风险相关,且生活方式和二甲双胍对T2DM风险的效果部分由这些变化介导。
要点
- 1年MetS-Z和腰围变化与1-5年T2DM风险关联最强(每增加1SD的HR均=1.80)。
- 1年MetS-Z、血糖和收缩压变化与CVD风险相关。
- 生活方式和二甲双胍对T2DM风险的效果由MetS-Z等变化介导。
核心结论
- DPP干预期间MetS严重程度指标的变化反映疾病风险改变,有助于追踪早期治疗反应和激励患者。
研究设计与样本
- 分析DPP中1996-1999年2476例糖尿病前期成人,随机接受生活方式、二甲双胍或安慰剂治疗2-3年,随访至2014年观察T2DM和CVD结局。
主要发现
- 基线MetS-Z及其组分与T2DM和CVD风险相关。
- 干预第1年MetS-Z及组分下降幅度:生活方式最大,其次二甲双胍,安慰剂最小。
- 1-5年T2DM风险与1年MetS-Z和腰围变化关联最强(每增加1SD的HR均=1.80)。
- CVD风险与1年MetS-Z、血糖和收缩压变化相关。
- 中介分析:生活方式对T2DM风险的效果由1年MetS-Z、腰围、血糖和甘油三酯变化介导;二甲双胍效果由MetS-Z和血糖介导。
临床怎么用
- 可用MetS-Z及其组分(尤其腰围、血糖)变化追踪糖尿病前期患者对生活方式或二甲双胍的早期反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We assessed whether changes in metabolic syndrome (MetS) severity during the treatment of prediabetes are associated with reduced risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). RESEARCH DESIGN AND METHODS: We analyzed data from the Diabetes Prevention Program (DPP) for 2,476 adults in 1996-1999 with prediabetes randomized to receive treatment with lifestyle modification, metformin, or placebo for 2-3 years and followed through 2014 for T2DM and CVD outcomes. We calculated effect sizes from baseline in a MetS severity z score (MetS-Z) and the individual MetS components, and assessed relationships between 1-year effect size and incident T2DM and CVD using hazard ratios (HRs) and mediation analysis. RESULTS: Baseline MetS-Z and its components were associated with risk of incident T2DM and CVD. During year 1 of intervention, MetS-Z and its components decreased most with lifestyle modification, followed by treatment with metformin and placebo. Risk of T2DM within 1-5 years was most strongly associated with 1-year changes in MetS-Z and waist circumference (both HRs for a 1 SD increase = 1.80), whereas the risk of CVD was associated with a 1-year change in MetS-Z, glucose, and systolic blood pressure. In mediation analyses, the effect of lifestyle modification on T2DM risk was mediated by 1-year changes in MetS-Z, waist circumference, glucose, and triglycerides, whereas the effect of metformin was mediated by MetS-Z and glucose. CONCLUSIONS: Changes in these risk indicators of MetS severity during intervention in the DPP reflect altered disease risk and may help in tracking earlier responses to treatment and in motivating patients.
引用
- DeBoer MD, Filipp SL, Gurka MJ, et al. Use of a Metabolic Syndrome Severity Z Score to Track Risk During Treatment of Prediabetes: An Analysis of the Diabetes Prevention Program. Diabetes Care. 2018. PMID: 30275282. doi:10.2337/dc18-1079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。